<DOC>
	<DOCNO>NCT00398840</DOCNO>
	<brief_summary>This open label , dose escalation study ARQ 171 administer via intravenous infusion ( IVI ) peripheral vein weekly . Patients advance solid tumor , refractory available therapy standard systemic therapy exists , enrol .</brief_summary>
	<brief_title>A Study ARQ 171 Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Signed write informed consent must obtain documented prior studyspecific screening procedure . A histologically cytologically confirm advanced solid tumor ≥ 18 year age Measurable disease define Response Evaluation Criteria Solid Tumors Karnofsky performance status ≥ 70 % Male female patient childproducing potential must agree use contraception avoidance pregnancy measure study 30 day participation . Females childbearing potential must negative serum pregnancy test . Laboratory result must meet study criterion . Anticancer chemotherapy , radiotherapy , immunotherapy , investigational agent within four week first infusion Surgery within 4 week prior first infusion Known untreated brain metastasis Pregnant breastfeeding Uncontrolled intercurrent illness , uncontrolled infection psychiatric illness/social situation would limit compliance study requirement Other cancer within last five year , exception adequately treat conebiopsied situ carcinoma cervix uteri basal squamous cell carcinoma skin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Solid Tumors</keyword>
	<keyword>advanced solid tumor</keyword>
</DOC>